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Use of Cardiac Computed
Tomography Prior to Percutaneous
Coronary Sinus Device Placement
for the Treatment of
Mitral Regurgitation
We would like to congratulate Harnek et al. (1) for showing
hat percutaneous implantation of the Monarc device (Edwards
ifesciences, Irvine, California) in the coronary sinus is not only
easible but also effectively reduces mitral regurgitation. The
nvestigators found that computed tomography (CT) docu-
ented the passage of the great cardiac vein (GCV) over an
btuse marginal artery in 55% of patients. The obtuse marginal
rtery was associated with angiographic coronary artery com-
ression in 15 patients and with myocardial infarction in 2
atients. In contrast, the coronary sinus/great cardiac vein
CS/GCV) did not pass over a major obtuse marginal artery in
9 patients, none of whom developed coronary artery compres-
ion. This study demonstrates that coronary artery compression
ay occur in patients in whom the GCV passes over a coronary
rtery. Cardiothoracic surgeons have appreciated for years that
urgical mitral valve annuloplasty may result in ischemia from
njury to the adjacent left circumflex artery (LCX) (2,3).
The potential for external coronary artery compression when
he CS/GCV runs over the obtuse marginal epicardial vessels
merged as the most important consideration for use of this
evice. The present study by Harnek et al. (1) shows that
oninvasive screening with CT is able to identify those patients
n whom the obtuse marginal vessels course under the CS/GCV
nd are therefore at risk for this complication. Accurate
re-procedural understanding of the CS/GCV anatomy as itrelates to the mitral valve, specifically the posterior mitral leaflet
and the LCX with its obtuse marginal (OM) branches, is vital
for this approach to be efficient and successful. We previously
developed a systematic method for describing the CS/GCV and
LCX/OM relationship with cardiac CT data (4). We found that a
large proportion of patients have the LCX/OM arterial distribution
traveling under the CS/GCV, and we found that this relationship
depends on coronary arterial dominance. In addition, we found that the
first OMwas under the CS/GCV in 26% to 61% of patients, depending
on the coronary dominance, compared with the second OM that was
under the CS/GCV in 13% to 28% of patients. It should also be noted
that a posterolateral branchmight also course under the CS in up to 53%
of patients, and thus may also be a potential artery that could be
jeopardized with a CS-based annuloplasty device.
Cardiac CT imaging of the CS/GCV using an organized
method should be considered an excellent tool to evaluate the
anatomic course of the coronary arteries in patients being evaluated
for percutaneous CS devices. The potential benefits of a minimally
invasive option to treat mitral regurgitation with percutaneous
transvenous catheter-based deployment of such annuloplasty de-
vices will need prospective studies to demonstrate that procedural
and late complications can indeed be avoided by using an image
guidance approach with cardiac CT.
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Reply
We thank Dr. Gopal and colleagues for their interest in our paper
(1) and agree that computed tomography is an important imaging
modality to screen patients at risk for coronary compression before
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Letters to the Editor594coronary sinus implantation with the MONARC device (Edwards
Lifesciences, Irvine, California).
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